MaxCyte, Inc.
("MaxCyte" or the "Company")
PDMR Dealing
ROCKVILLE, MD, June 12, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 7 June 2024 and 10 June 2024, Maher Masoud, President and Chief Executive Officer of the Company, using personal funds, purchased 100,000 shares on the open market of common stock in the Company ("Common Stock"). The 100,000 shares of Common Stock were purchased at an average price of $4.8907 per Common stock.
Following the purchase of Common Stock, Maher Masoud holds a total of 100,000 Common Stock representing approximately 0.1 percent of the issued share capital of the Company. Maher Masoud holds a further 1,074,200 options over Common Stock and 400,000 performance stock units.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400
|
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700
|
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Maher Masoud | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| President, CEO and Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase of common stock | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Purchase Price(s) range | Volume(s) | | |
| | | $4.84-$4.95 | 29,557 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 29,557 | ||||
| | | ||||
| - Price | $4.866 | ||||
| | | ||||
| e)
| Date of the transaction
| 7 June 2024 | |||
| f)
| Place of the transaction
| USStock Exchange, Nasdaq | |||
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Maher Masoud | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| President, CEO and Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase of common stock | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Purchase Price(s) range | Volume(s) | | |
| | | $4.77-$5.00 | 70,443 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 70,443 | ||||
| | | ||||
| - Price | $4.9011 | ||||
| | | ||||
| e)
| Date of the transaction
| 10 June 2024 | |||
| f)
| Place of the transaction
| USStock Exchange, Nasdaq | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
